Nitrogen Bonded Directly To The Five-membered Hetero Ring By Nonionic Bonding Patents (Class 514/426)
-
Patent number: 7388112Abstract: The synthesis and use of a novel class of tumor necrosis factor (TNF?) inhibitors and immunomodulators are provided. Examples are those having the structures: wherein a, b and c are integers from 0 to 12, X equals NH or CHNH2, R1 and R2 each is a hydrogen or a C1 to C20 aliphatic; aliphatic amine; an alicyclic; aromatic; heterocycle; and halogenated forms thereof; and wherein, a, b and c are integers from 0 to 12; R1, R2, R3, and R4 each is a hydrogen or a C1 to C20; aliphatic amine; an alicyclic; aromatic; a heterocycle; and halogenated forms thereof.Type: GrantFiled: July 1, 2005Date of Patent: June 17, 2008Assignee: MediQuest Therapeutics, Inc.Inventors: Mark R. Burns, Maralee McVean, Kevin Kennedy, Arthur Yeung, Bruce H. Devens
-
Patent number: 7381741Abstract: 3-amino-2-phenylpyrrolidine compounds useful as NK-1 antagonists, with pharmaceutical compositions and methods of treatment comprising same, are disclosed.Type: GrantFiled: May 25, 2005Date of Patent: June 3, 2008Assignee: Pfizer IncInventors: John Michael Humphrey, Thomas Allen Chappie
-
Publication number: 20080119476Abstract: Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH2—.Type: ApplicationFiled: July 1, 2005Publication date: May 22, 2008Inventors: Amjad Ali, Joann M. Napolitano, Qiaolin Deng, Zhijian Lu, Peter J. Sinclair, Gayle E. Taylor, Christopher F. Thompson, Nazia Quraishi, Cameron J. Smith, Julianne A. Hunt, Adrian A. Dowst, Yi-Heng Chen, Hong Li
-
Patent number: 7329685Abstract: The invention relates to compounds of formula (I): wherein substituents are as defined.Type: GrantFiled: June 17, 2004Date of Patent: February 12, 2008Assignee: Glaxo Group LimitedInventors: Alan David Borthwick, Chuen Chan, Henry Anderson Kelly, Savvas Kleanthous, Andrew McMurtrie Mason, Nigel Stephen Watson
-
Patent number: 7326729Abstract: The present invention is directed to a compound having the general structure of formula (1): useful for the treatment, prevention or amelioration of a CXCR1 or CXCR2 chemokine-mediated disease.Type: GrantFiled: May 11, 2005Date of Patent: February 5, 2008Assignee: Schering CorporationInventors: Jianhua Chao, Arthur G. Taveras, Cynthia J. Aki
-
Publication number: 20070270440Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor.Type: ApplicationFiled: May 18, 2007Publication date: November 22, 2007Applicant: WyethInventors: Derek Cecil Cole, Magda Asselin, Joseph Raymond Stock, Jin-In Kim
-
Patent number: 7267826Abstract: The present invention relates to a microbicide composition for plants, containing at least two active ingredient components in an amount producing synergistic activity, together with an appropriate filler, wherein component I is the compound 2-[?-{[(?-methyl-3-trifluoromethyl-benzyl)imino]-oxy}-o-tolyl]-glyoxylic acid-methylester-O-methyloxime, and component II is a compound selected from the group consisting of IIA) 5,7-dichloro-4-(4-fluorophenoxy)quinoline (“Quinoxyfen”); IIB) 4-cyclopropyl-6-methyl-N-phenyl-2-pyrimidinamine (“Cyprodinil”); IIC) benzo(1,2,3) thiadiazole-7-carbothio-acid-S-methylester (“Acibenzolar-S-methyl”); IID) 3-anilino-5-methyl-5-(4-phenoxyphenyl)-1,3-oxazolidine-2,4-dione (“Famoxadone”); IIE) 8-(1,1-dimethylethyl)-N-ethyl-N-propyl-1,4-dioxaspiro[4.Type: GrantFiled: December 12, 2005Date of Patent: September 11, 2007Assignee: Bayer CropScience AGInventors: Paul Margot, Gertrude Knauf-Beiter
-
Patent number: 7256191Abstract: The subject invention provides compounds which are easily metabolized by the metabolic drug detoxification systems. Particularly, fluvoxamine analogs which have been designed to include esters within the structure of the compounds are taught. Also provided are methods of treating depression and affective disorders, such as obsessive compulsive disorder. Pharmaceutical compositions of the fluvoxamine analogs are also taught.Type: GrantFiled: August 31, 2004Date of Patent: August 14, 2007Assignee: Aryx TherapeuticsInventor: Pascal Druzgala
-
Patent number: 7250443Abstract: New pyrrole based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.Type: GrantFiled: August 21, 2003Date of Patent: July 31, 2007Assignee: Chiron CorporationInventors: Manoj C. Desai, Simon Ng, Zhi-Jie Ni, Keith B. Pfister, Savithri Ramurthy, Sharadha Subramanian, Allan S. Wagman
-
Patent number: 7223788Abstract: The invention relates to substituted N-aryl heterocycles and to the physiologically tolerated salts and physiologically functional derivatives thereof. Compounds of the formula I in which the radicals have the stated meanings, the N-oxides and the physiologically tolerated salts thereof and process for the preparation thereof are described. The compounds are suitable for example as anorectic agents.Type: GrantFiled: February 17, 2004Date of Patent: May 29, 2007Assignee: Sanofi-Aventis Deutschland GmbHInventors: Lothar Schwink, Siegfried Stengelin, Matthias Gossel, Thomas Boehme, Gerhard Hessler, Petra Stahl, Dirk Gretzke
-
Patent number: 7214701Abstract: The invention relates to insecticidal mixtures for protecting plants against attack by pests comprising (a) compounds of the formula (I) ?in which W, X, Y, Z, A, B, D and G are each as defined in the disclosure, and (b) specified agonists or antagonists of nicotinic acetylcholine receptors.Type: GrantFiled: June 25, 2004Date of Patent: May 8, 2007Assignee: Bayer CropScience AGInventors: Reiner Fischer, Christoph Erdelen
-
Patent number: 7198803Abstract: Medicinal preparations containing a drug 2-amino-3-cyano-5-2(2-fluorophenyl) -4-methylpyrrole wherein the QOL and compliance of patients taking this drug can be improved and an unnecessary increase in the drug concentration in the plasma can be prevented by sustaining the release speed of the drug in vivo and lowering the administration frequency of the drug. That is, sustained release oral preparations containing 2-amino-3-cyano-5-(2-fluorophenyl)-4-methylpyrrole as the active ingredient.Type: GrantFiled: March 19, 2001Date of Patent: April 3, 2007Assignee: Nippon Shinyaku Co., Ltd.Inventors: Hiroyuki Yasuura, Kenya Akada, Shogo Izumi
-
Patent number: 7183298Abstract: This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: (I) A is an aryl group; Q1 is a covalent bond or an aryl leader group; J is a sulfonamide linkage selected from: —S(?O)2NR1— and —NR1S(?O)2—; R1 is a sulfonamido substituent; and, Q2 is an acid leader group; with the proviso that if J is —S(?O)2NR1—, then Q1 is an aryl leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.Type: GrantFiled: September 30, 2004Date of Patent: February 27, 2007Assignee: Topotarget UK LimitedInventors: Clare J Watkins, Maria Rosario Romero-Martin, Kathryn G Moore, James Ritchie, Paul W Finn, Ivars Kalvinsh, Einars Loza, Klara Dikovska, Vija Gailite, Maxim Vorona, Irina Piskunova, Igor Starchenkov, Victor Andrianov, C. John Harris, James E. S. Duffy
-
Patent number: 7126010Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of inflammatory diseases such as asthma and other allergic diseases.Type: GrantFiled: January 21, 2005Date of Patent: October 24, 2006Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Dean A Wacker, John V Duncia, Joseph B Santella, III., Daniel S Gardner
-
Patent number: 7115754Abstract: The present invention relates to novel pyrrolidine derivative of formula (I), its geometrical isomers, its optically active forms as enantiomers, diastereomers, mixtures of these and its racemate forms, as well as salts thereof, wherein R1 is selected from the group comprising or consisting of H and C1–C6-alkyl, for the prevention and/or treatment of preterm labor, premature birth or dysmenorrheaType: GrantFiled: July 4, 2003Date of Patent: October 3, 2006Assignee: Applied Research Systems ARS Holding N.V.Inventors: Catherine Jorand-Lebrun, Jerome Dorbais, Anna Quattropani, Matthias Schwarz, Delphine Valognes
-
Patent number: 7078414Abstract: The present invention relates to 3-guanidinocarbonyl-1-heteroaryl-pyrrole derivatives of formula (I) wherein R1 to R3 and Ar are as defined herein, pharmaceutical compositions comprising such derivatives, methods of treatment comprising administering such derivatives, and processes for their preparationType: GrantFiled: December 23, 2003Date of Patent: July 18, 2006Assignee: Sanofi-Aventis Deutschland GmbHInventors: Heinz-Werner Kleemann, Pascal Desmazeau, Jean-Christophe Carry, Baptiste Ronan, Serge Mignani, Jean Bououerel, Arielle Genevois-Borella
-
Patent number: 7045521Abstract: The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.Type: GrantFiled: November 12, 2003Date of Patent: May 16, 2006Assignee: Bristol-Myers Squibb Pharma CompanyInventor: Robert Cherney
-
Patent number: 7005439Abstract: The invention provides compounds of general formula (I) wherein m, n, Z1, Z2, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in the specification, process for their preparation, pharmaceutical compositions containing them and their use in therapy.Type: GrantFiled: June 14, 2001Date of Patent: February 28, 2006Assignee: AstraZeneca ABInventors: Tomas Eriksson, Krister Henriksson
-
Patent number: 6992081Abstract: The present invention is directed toward substituted hydroxyethylene compounds of formulas (XII) (XIII), and (XIV) useful in treating Alzheimer's disease and other similar diseases.Type: GrantFiled: September 21, 2001Date of Patent: January 31, 2006Assignee: Elan Pharmaceuticals, Inc.Inventors: Roy Hom, Shumeye Mamo, Jay Tung, Andrea Gailunas, Varghese John, Lawrence Fang
-
Patent number: 6982263Abstract: Disclosed are novel nitrile compounds of formula (I) further defined herein, which compounds are useful as reversible inhibitors of cysteine proteases such as cathepsin K, S, F, L and B. These compounds are useful for treating diseases and pathological conditions exacerbated by these proteases such as, but not limited to, osteoporosis, rheumatoid arthritis, multiple sclerosis, asthma and other autoimmune diseases, Alzheimer's disease, atherosclerosis. Also disclosed are processes for making such novel compounds.Type: GrantFiled: June 4, 2002Date of Patent: January 3, 2006Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Eugene R. Hickey, Younes Bekkali, Usha R. Patel, Denice Mary Spero, David S. Thomson, Erick Richard Roush Young
-
Patent number: 6974825Abstract: Compounds of general formula (I) wherein m is 0 or 1, and n is 1 or 2; are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.Type: GrantFiled: July 29, 2003Date of Patent: December 13, 2005Assignee: AstraZeneca Canada Inc.Inventors: Benjamin Pelcman, Edward Roberts
-
Patent number: 6949553Abstract: The present invention relates to aliphatic compounds of the formula I, or stereoisomers thereof, or their pharmaceutically acceptable salts: wherein A represents an optionally substituted CH3CnH(2n-2m)— (wherein n denotes an integer of 4 to 22, and m represents an unsaturation number which is an integer of 0 to 7), l represents an integer of 0 to 10, s represents 0 or 1, provided that when s is 0, p+q=4 or 5, but when s is 1, p+q=3 or 4, and in each case, either p or q is an integer of 1 or more, R represents an alkyl group having 1 to 10 carbon atoms which may be straight-chain or branched-chain, and RA represents hydrogen or an alkyl group having 1 to 10 carbon atoms which may be straight-chain or branched-chain, and their use in suppression of platelet aggregation, in suppression of inflammation, and in prevention and treatment of circulatory diseases.Type: GrantFiled: June 18, 2002Date of Patent: September 27, 2005Assignee: Maruha CorporationInventors: Tadakazu Tamai, Kazuyoshi Yoshikai, Masazumi Nishikawa, Kunio Ogasawara, Itsuki Murota
-
Patent number: 6939891Abstract: The invention relates to certain novel compounds having Vanilloid Receptor (VR1) antagonist activity, processes for their preparation, to compositions containing them and to their use in the treatment of various disorders.Type: GrantFiled: May 2, 2002Date of Patent: September 6, 2005Assignee: SmithKline Beecham, PLCInventors: Harshad Kantilal Rami, Mervyn Thompson, Paul Adrian Wyman
-
Patent number: 6919483Abstract: The synthesis and use of a novel class of tumor necrosis factor (TNF?) inhibitors and immunomodulators are provided. These compounds have pharmacological applications as well as uses in assays relating to TNF? and other involved cytokines. As pharmaceuticals, these compounds are used to treat inflammatory, infectious, autoimmune or other proliferative diseases and conditions related to the unwanted presence or activity of TNF? and/or one or more other involved cytokines, alone or in combination with other agents.Type: GrantFiled: May 23, 2003Date of Patent: July 19, 2005Assignee: Mediquest Therapeutics, Inc.Inventors: Mark R. Burns, Maralee McVean, Kevin J. Kennedy, Arthur Yeung, Bruce H. Devens
-
Patent number: 6916814Abstract: Disclosed are methods of treating certain cytokine mediated diseases or conditions using novel aromatic heterocyclic compounds of the formula(I) wherein Ar1,Ar2,L,Q and X are described herein.Type: GrantFiled: July 1, 2002Date of Patent: July 12, 2005Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Neil Moss, John Robinson Regan
-
Patent number: 6911458Abstract: The invention provides compounds of general formula (I) wherein m, n, Q, Z1, Z2, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.Type: GrantFiled: June 14, 2001Date of Patent: June 28, 2005Assignee: Astra ZenecaInventors: Tomas Eriksson, Tomas Klingstedt, Tesfaledet Mussie
-
Patent number: 6878733Abstract: The present invention features formulations of indolinones which compounds are ionizable as free acids or free bases. The formulation is suitable for parenteral or oral administration, wherein the formulation comprises an ionizable substituted indolinone, and a pharmaceutically acceptable carrier therefor. The term “ionizable substituted indolinone” includes pyrrole substituted 2-indolinones which, in addition to being otherwise optionally substituted on both the pyrrole and 2-indolinone portions of the compound, are necessarily substituted on the pyrrole moiety with one or more hydrocarbon chains which themselves are substituted with at least one polar group. The formulations and the compounds themselves are useful for the treatment of protein kinase related disorders as discussed herein.Type: GrantFiled: November 21, 2000Date of Patent: April 12, 2005Assignee: Sugen, Inc.Inventors: Narmada Shenoy, Waranush Sorasuchart, Arun Koparkar
-
Patent number: 6867221Abstract: A cyclic amine compound represented by the following general formula (1): wherein, R1, R2 and R3 each independently represent a hydrogen atom or an alkoxy group; W1 and W2 each independently represent N or CH; X represents O, NR4, CONR4 or NR4CO; R4 represents a hydrogen atom, or an alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl group; and l, m and n each represents a number of 0 or 1, a salt thereof and a hydrate thereof are provided. These compounds have inhibitory effects on both cell adhesion and cell infiltration and are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents or the like.Type: GrantFiled: July 10, 2002Date of Patent: March 15, 2005Assignee: Kowa Co., Ltd.Inventors: Tatsuhiko Kodama, Masahiro Tamura, Toshiaki Oda, Yukiyoshi Yamazaki, Masahiro Nishikawa, Shunji Takemura, Takeshi Doi, Yoshinori Kyotani, Masao Ohkuchi
-
Patent number: 6864380Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of inflammatory diseases such as asthma and other allergic diseases.Type: GrantFiled: July 3, 2003Date of Patent: March 8, 2005Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Dean A Wacker, John V Duncia, Joseph B Santella, III, Daniel S Gardner
-
Patent number: 6864276Abstract: The invention relates to insecticidal mixtures for protecting plants against attack by pests comprising (a) compounds of the formula (I) ?in which W, X, Y, Z, A, B, D and G are each as defined in the disclosure, and (b) agonists or antagonists of nicotinic acetylcholine receptors.Type: GrantFiled: May 7, 2001Date of Patent: March 8, 2005Assignee: Bayer Cropscience AGInventors: Reiner Fischer, Christoph Erdelen
-
Patent number: 6858623Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R2, R3, R4, R5, R6, R7, R8, Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.Type: GrantFiled: May 29, 2003Date of Patent: February 22, 2005Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Younes Bekkali, Eugene R. Hickey, Weimin Liu, Usha R. Patel, Denice M. Spero, Sanxing Sun, David S. Thomson, Yancey D. Ward, Erick R. R. Young
-
Patent number: 6835727Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of Cathepsins K and L. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.Type: GrantFiled: August 23, 2002Date of Patent: December 28, 2004Assignees: Merck Frosst Canada & Co., Banyu Pharmaceutical Co., Ltd., Axys Pharmaceuticals, Inc.Inventors: Osamu Okamoto, Jean-Pierre Falgueyret, Renata Marcella Oballa, Petpiboon Prasit, Robert Rydzewski
-
Publication number: 20040259908Abstract: The present invention relates to a 2-phenyl-3-heteroarylpropionic acid derivative or a salt thereof, and also relates to a pharmaceutical agent and a VLA-4 and/or LPAM-1 antagonist each of which contains the same as an active ingredient.Type: ApplicationFiled: July 27, 2004Publication date: December 23, 2004Inventors: Satoru Ikegami, Yoichiro Hoshina
-
Publication number: 20040254236Abstract: Provided are 5-membered heterocycle-based p38 kinase, including p38&agr; and p38&bgr; kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.Type: ApplicationFiled: June 2, 2004Publication date: December 16, 2004Inventors: Qing Dong, Fabrice Pierre, Jianqiang Wang
-
Publication number: 20040242666Abstract: The present invention relates to compounds of the Formula 1Type: ApplicationFiled: May 12, 2004Publication date: December 2, 2004Applicants: Pfizer, Inc., Pfizer Products, Inc.Inventor: Yuhpyng Liang Chen
-
Publication number: 20040235908Abstract: Disclosed are compounds of the formula: 1Type: ApplicationFiled: June 16, 2004Publication date: November 25, 2004Applicant: Schering CorporationInventors: Arthur G. Taveras, Cynthia J. Aki, Richard W. Bond, Jianping Chao, Michael Dwyer, Johan A. Ferreira, Jonathan A. Pachter, John J. Baldwin, Bernd Kaiser, Ge Li, J. Robert Merritt, Kingsley H. Nelson, Laura L. Rokosz
-
Publication number: 20040235836Abstract: The present application describes modulators of MCP-1 of formula (I): 1Type: ApplicationFiled: April 29, 2004Publication date: November 25, 2004Inventor: Robert J. Cherney
-
Publication number: 20040235825Abstract: A carboxylic acid derivative of formula (I) 1Type: ApplicationFiled: June 10, 2004Publication date: November 25, 2004Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Kousuke Tani, Masaki Osada, Kaoru Kobayashi, Masami Narita, Mikio Ogawa
-
Publication number: 20040220222Abstract: The invention relates to malonamide derivatives of formula 1Type: ApplicationFiled: January 29, 2004Publication date: November 4, 2004Inventors: Guido Galley, Annick Goergler, Helmut Jacobsen, Eric Argirios Kitas, Jens-Uwe Peters
-
Publication number: 20040204477Abstract: A compound of formula (I) is provided which is able to interact with &bgr;-catenin/TCF-4 binding site, having a structure essentially equivalent to a pharmacophore (IA), as herein described.Type: ApplicationFiled: May 24, 2004Publication date: October 14, 2004Inventors: Juergen Moll, Stefan Knapp, Claudio Dalvit, Jean-Yves Trosset, Michael Sundstrom, Sergio Mantegani
-
Publication number: 20040186140Abstract: The present application describes modulators of MCP-1 of formula (I): 1Type: ApplicationFiled: February 11, 2004Publication date: September 23, 2004Inventors: Robert J. Cherney, Percy H. Carter, John V. Duncia, Daniel S. Gardner, Joseph B. Santella
-
Publication number: 20040180871Abstract: The present invention provides compositions and their use in the treatment of inflammatory diseases caused by T-cell proliferation such as sepsis, inflammatory bowel diseases, autoimmune encephalomyelitis, or lupus.Type: ApplicationFiled: December 23, 2003Publication date: September 16, 2004Applicant: Genzyme CorporationInventors: Mark M. Staveski, Robert J. Miller, Sharon R. Nahill
-
Publication number: 20040180889Abstract: The invention is directed to modulators, e.g., inhibitors, of Pin1 and Pin1-related proteins and the use of such modulators for treatment of Pin1 associated states, e.g., for the treatment of cancer.Type: ApplicationFiled: March 3, 2003Publication date: September 16, 2004Applicant: Pintex Pharmaceuticals, Inc.Inventors: Robert K. Suto, Timothy D. McKee
-
Publication number: 20040171678Abstract: Dithiocarbamate, particularly tetraethylthiuram disulfide, and thiocarbamate anions strongly inhibit the growth of cancer cells of a variety of cell types. Such inhibitory effect is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide to reduce tumor growth, and to potentiate the effect of other anticancer agents.Type: ApplicationFiled: February 25, 2004Publication date: September 2, 2004Applicant: Charlotte-Mecklenburg Hospital Authority d/b/a Carolinas Medical CenterInventor: Thomas Preston Kennedy
-
Publication number: 20040167180Abstract: Disclosed and claimed is a method for treating tumors using sulfonylamino-substituted N-aryl- or heteroarylcarboxamide derivatives.Type: ApplicationFiled: February 23, 2004Publication date: August 26, 2004Applicant: Compass Pharmaceuticals, LLCInventor: Irwin Braude
-
Publication number: 20040152740Abstract: The present invention relates to compounds of Formula 1: 1Type: ApplicationFiled: September 8, 2003Publication date: August 5, 2004Applicant: NPS Allelix CorporationInventors: Methvin Isaac, Tao Xin, Tomislav Stefanac, Anne O'Brien, Kathleen Da Silva-Turcot, Jalaj Arora, Shawn Maddaford, Abdelmalik Slassi
-
Publication number: 20040152741Abstract: The present invention relates to compounds of Formula 1, 1Type: ApplicationFiled: September 8, 2003Publication date: August 5, 2004Applicant: NPS Allelix CorporationInventors: Methvin Isaac, Tao Xin, Louise Edwards, Leah Begleiter, Tomislav Stefanac, Anne O'Brien, Kathleen Da Silva-Turcot, Jalaj Arora, Shawn Maddaford, Abdelmalik Slassi
-
Publication number: 20040147576Abstract: Novel compounds of formula (I) to (VI), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I)-(VI), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: January 15, 2004Publication date: July 29, 2004Applicant: Portola Pharmaceuticals, Inc.Inventors: Robert M. Scarborough, Hans-Michael Jantzen, Wolin Huang, David M. Sedlock, Charles Marlowe
-
Publication number: 20040138244Abstract: This invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. Other SARM compounds have been found to have an unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor.Type: ApplicationFiled: October 14, 2003Publication date: July 15, 2004Inventors: James T. Dalton, Duane D. Miller
-
Publication number: 20040138292Abstract: Chemical intermediates which are of use in the production of quinolone carboxylic acid derivatives having antibacterial activity.Type: ApplicationFiled: December 23, 2003Publication date: July 15, 2004Applicant: SB Pharmco Puerto Rico Inc of the United States Corporation Company.Inventors: Trevor Grinter, Simon Howie